Thomas Cerny
Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma
Waeckerle-Men Y, Groettrup M, Ludewig B, Cerny T, Ackermann D, Schmid H, Böhme C, von Moos R, Fopp M, Uetz-von Allmen E, Gillessen Sommer S. Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma. Cancer immunology, immunotherapy : CII 2006; 55:1524-33.
Dec 1, 2006Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma
Dec 1, 2006Cancer immunology, immunotherapy : CII 2006; 55:1524-33
Waeckerle-Men Ying, Groettrup Marcus, Ludewig Burkhard, Cerny Thomas, Ackermann Daniel, Schmid Hans-Peter, Böhme Christel, von Moos Roger, Fopp Markus, Uetz-von Allmen Edith, Gillessen Sommer Silke
Treatment of advanced soft-tissue sarcomas using a combined strategy of high-dose ifosfamide, high-dose doxorubicin and salvage therapies
Leyvraz S, Pestalozzi B, Dietrich D, Cerny T, Wernli M, Sessa C, Fey M, Christinat A, Honegger H, Guillou L, Herrmann R, Swiss Group for Clinical Cancer Research (SAKK). Treatment of advanced soft-tissue sarcomas using a combined strategy of high-dose ifosfamide, high-dose doxorubicin and salvage therapies. British journal of cancer 2006; 95:1342-7.
Nov 20, 2006Treatment of advanced soft-tissue sarcomas using a combined strategy of high-dose ifosfamide, high-dose doxorubicin and salvage therapies
Nov 20, 2006British journal of cancer 2006; 95:1342-7
Leyvraz S, Pestalozzi B, Dietrich D, Cerny Thomas, Wernli M, Sessa C, Fey M F, Christinat A, Honegger H P, Guillou L, Herrmann R, Swiss Group for Clinical Cancer Research (SAKK)
Successful treatment of acute disseminated intravascular coagulation in a patient with metastatic melanoma
Schlaeppi M, Korte W, von Moos R, Cerny T, Gillessen Sommer S. Successful treatment of acute disseminated intravascular coagulation in a patient with metastatic melanoma. Onkologie 2006; 29:531-3.
Nov 1, 2006Successful treatment of acute disseminated intravascular coagulation in a patient with metastatic melanoma
Nov 1, 2006Onkologie 2006; 29:531-3
Schlaeppi Marc, Korte Wolfgang, von Moos Roger, Cerny Thomas, Gillessen Sommer Silke
Sequential high dose chemotherapy as initial treatment for aggressive sub-types of non-Hodgkin lymphoma: results of the international randomized phase III trial (MISTRAL)
Betticher D, Cerny T, Maibach R, Cina S, Cogliatti S, Kovascovics T, von Rohr A, Beck J, Aulitzky W, Kaiser U, Dyer M, Kaufmann M, Radford J, Martinelli G, Linch D. Sequential high dose chemotherapy as initial treatment for aggressive sub-types of non-Hodgkin lymphoma: results of the international randomized phase III trial (MISTRAL). Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006; 17:1546-52.
Oct 1, 2006Sequential high dose chemotherapy as initial treatment for aggressive sub-types of non-Hodgkin lymphoma: results of the international randomized phase III trial (MISTRAL)
Oct 1, 2006Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006; 17:1546-52
Betticher D C, Cerny Thomas, Maibach R, Cina S, Cogliatti S B, Kovascovics T, von Rohr A, Beck J, Aulitzky W E, Kaiser U, Dyer M J S, Kaufmann M, Radford J A, Martinelli G, Linch D C
Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group
Cannabis-In-Cachexia-Study-Group, Reif M, Schnelle M, Ko Y, Meissner W, Ruhstaller T, Ernst G, Possinger K, Luftner D, Strasser F, Cerny T. Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006; 24:3394-400.
Jul 20, 2006Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group
Jul 20, 2006Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006; 24:3394-400
Cannabis-In-Cachexia-Study-Group, Reif Marcus, Schnelle Martin, Ko You-Dschun, Meissner Winfried, Ruhstaller Thomas, Ernst Gernot, Possinger Kurt, Luftner Diana, Strasser Florian, Cerny Thomas
Palliative in-patient cancer treatment in an anthroposophic hospital: II. Quality of life during and after stationary treatment, and subjective treatment benefits
Heusser P, Braun S, Bertschy M, Burkhard R, Ziegler R, Helwig S, van Wegberg B, Cerny T. Palliative in-patient cancer treatment in an anthroposophic hospital: II. Quality of life during and after stationary treatment, and subjective treatment benefits. Forschende Komplementärmedizin (2006) 2006; 13:156-66.
Jun 1, 2006Palliative in-patient cancer treatment in an anthroposophic hospital: II. Quality of life during and after stationary treatment, and subjective treatment benefits
Jun 1, 2006Forschende Komplementärmedizin (2006) 2006; 13:156-66
Heusser Peter, Braun Sarah Berger, Bertschy Manuel, Burkhard René, Ziegler Renatus, Helwig Silke, van Wegberg Brigitte, Cerny Thomas
Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study
Betticher D, Weder W, Stupp R, Egli F, Furrer M, Honegger H, Wernli M, Cerny T, Ris H, Stahel R, Spiliopoulos A, Roth A, Hsu Schmitz S, Tötsch M, Hansen E, Joss C, von Briel C, Schmid R, Pless M, Habicht J, Swiss Group for Clinical Cancer Research (SAKK). Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study. British journal of cancer 2006; 94:1099-106.
Apr 24, 2006Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study
Apr 24, 2006British journal of cancer 2006; 94:1099-106
Betticher D C, Weder W, Stupp R, Egli F, Furrer M, Honegger H, Wernli M, Cerny Thomas, Ris H-B, Stahel R, Spiliopoulos A, Roth A D, Hsu Schmitz S-F, Tötsch M, Hansen E, Joss C, von Briel C, Schmid R A, Pless M, Habicht J, Swiss Group for Clinical Cancer Research (SAKK)
A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma
Jermann M, Bauer J, Rhyner K, Egli F, Morant R, Gillessen Sommer S, Jörger M, Cerny T, Salzberg M, Stahel R, Pless M. A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma. Cancer chemotherapy and pharmacology 2006; 57:533-9.
Apr 1, 2006A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma
Apr 1, 2006Cancer chemotherapy and pharmacology 2006; 57:533-9
Jermann Monika, Bauer Jean A, Rhyner Kaspar, Egli Fritz, Morant Rudolf, Gillessen Sommer Silke, Jörger Markus, Cerny Thomas, Salzberg Marc, Stahel Rolf A, Pless Miklos
Palliative in-patient cancer treatment in an anthroposophic hospital: I. Treatment patterns and compliance with anthroposophic medicine
Heusser P, Braun S, Ziegler R, Bertschy M, Helwig S, van Wegberg B, Cerny T. Palliative in-patient cancer treatment in an anthroposophic hospital: I. Treatment patterns and compliance with anthroposophic medicine. Forschende Komplementärmedizin (2006) 2006; 13:94-100.
Apr 1, 2006Palliative in-patient cancer treatment in an anthroposophic hospital: I. Treatment patterns and compliance with anthroposophic medicine
Apr 1, 2006Forschende Komplementärmedizin (2006) 2006; 13:94-100
Heusser Peter, Braun Sarah Berger, Ziegler Renatus, Bertschy Manuel, Helwig Silke, van Wegberg Brigitte, Cerny Thomas
Long-term results of a multicenter SAKK trial on high-dose ifosfamide and doxorubicin in advanced or metastatic gynecologic sarcomas
Leyvraz S, Honegger H, Dietrich D, Fey M, Sessa C, Cerny T, Lissoni A, Jundt G, Zweifel M, Swiss Group for Clinical Cancer Research. Long-term results of a multicenter SAKK trial on high-dose ifosfamide and doxorubicin in advanced or metastatic gynecologic sarcomas. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006; 17:646-51.
Apr 1, 2006Long-term results of a multicenter SAKK trial on high-dose ifosfamide and doxorubicin in advanced or metastatic gynecologic sarcomas
Apr 1, 2006Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006; 17:646-51
Leyvraz S, Honegger H P, Dietrich D, Fey M, Sessa C, Cerny Thomas, Lissoni A, Jundt G, Zweifel M, Swiss Group for Clinical Cancer Research
Spirituality, psychotherapy and music in palliative cancer care: research projects in psycho-oncology at an oncology center in Switzerland
Renz M, Schütt Mao M, Cerny T. Spirituality, psychotherapy and music in palliative cancer care: research projects in psycho-oncology at an oncology center in Switzerland. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2005; 13:961-6.
Dec 1, 2005Spirituality, psychotherapy and music in palliative cancer care: research projects in psycho-oncology at an oncology center in Switzerland
Dec 1, 2005Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2005; 13:961-6
Renz Monika, Schütt Mao Miriam, Cerny Thomas
Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK)
Ghielmini M, Cerny T, Wernli M, Ketterer N, Lohri A, Stahel R, Martinelli G, Fey M, Cogliatti S, Léger-Falandry C, Leoncini-Franscini L, Salles G, Rufibach K, Schmitz S. Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK). Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005; 16:1675-82.
Oct 1, 2005Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK)
Oct 1, 2005Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005; 16:1675-82
Ghielmini M, Cerny Thomas, Wernli M, Ketterer N, Lohri A, Stahel R, Martinelli G, Fey M, Cogliatti S, Léger-Falandry C, Leoncini-Franscini L, Salles G, Rufibach K, Schmitz S-F Hsu
Reply to: Hasman A and Holm S. Nicotine conjugate vaccine: is there a right to a smoking future?
Cerny T. Reply to: Hasman A and Holm S. Nicotine conjugate vaccine: is there a right to a smoking future?. Journal of medical ethics 2005; 31:558.
Sep 1, 2005Reply to: Hasman A and Holm S. Nicotine conjugate vaccine: is there a right to a smoking future?
Sep 1, 2005Journal of medical ethics 2005; 31:558
Cerny Thomas
Spirituality, Psychotherapy, and Music in Palliative Cancer Care
Renz M, Schütt Mao M, Cerny T. Spirituality, Psychotherapy, and Music in Palliative Cancer Care - Research Projects in Psycho-oncology at an Oncology Center in Switzerland. Supportive Care in Cancer 2005; 13(2005):961-966.
Aug 1, 2005Spirituality, Psychotherapy, and Music in Palliative Cancer Care
Aug 1, 2005Supportive Care in Cancer 2005; 13(2005):961-966
Renz Monika, Schütt Mao Miriam, Cerny Thomas
Komplementärmedizin in der Onkologie - eine Einführung
Schlaeppi M, Jungi F, Cerny T. Komplementärmedizin in der Onkologie - eine Einführung. Swiss Medical Forum 2005; 5:686-694.
Jun 1, 2005Komplementärmedizin in der Onkologie - eine Einführung
Jun 1, 2005Swiss Medical Forum 2005; 5:686-694
Schlaeppi Marc, Jungi Felix, Cerny Thomas
Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature
D'Addario G, Pintilie M, Leighl N, Feld R, Cerny T, Shepherd F. Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005; 23:2926-36.
May 1, 2005Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature
May 1, 2005Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005; 23:2926-36
D'Addario Giannicola, Pintilie Melania, Leighl Natasha B, Feld Ronald, Cerny Thomas, Shepherd Frances A
Phase I study and pharmacokinetic of CHS-828, a guanidino-containing compound, administered orally as a single dose every 3 weeks in solid tumours: an ECSG/EORTC study
Ravaud A, Cerny T, Terret C, Wanders J, Bui B, Hess D, Droz J, Fumoleau P, Twelves C. Phase I study and pharmacokinetic of CHS-828, a guanidino-containing compound, administered orally as a single dose every 3 weeks in solid tumours: an ECSG/EORTC study. European journal of cancer (Oxford, England : 1990) 2005; 41:702-7.
Mar 1, 2005Phase I study and pharmacokinetic of CHS-828, a guanidino-containing compound, administered orally as a single dose every 3 weeks in solid tumours: an ECSG/EORTC study
Mar 1, 2005European journal of cancer (Oxford, England : 1990) 2005; 41:702-7
Ravaud Alain, Cerny Thomas, Terret Catherine, Wanders Jantien, Bui Binh Nguyen, Hess Dagmar, Droz Jean-Pierre, Fumoleau Pierre, Twelves Chris
Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK)
Ghielmini M, Cerny T, Bargetzi M, Ketterer N, Stahel R, Pichert G, Schefer H, Betticher D, Fey M, Waltzer U, Bertoni F, Cogliatti S, Schmitz S, Swiss Group for Clinical Cancer Research. Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005; 23:705-11.
Feb 1, 2005Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK)
Feb 1, 2005Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005; 23:705-11
Ghielmini Michele, Cerny Thomas, Bargetzi Mario, Ketterer Nicolas, Stahel Rolf, Pichert Gabriella, Schefer Hubert, Betticher Daniel C, Fey Martin F, Waltzer Ursula, Bertoni Francesco, Cogliatti Sergio, Schmitz Shu-Fang Hsu, Swiss Group for Clinical Cancer Research
Resection of skin metastases from gastric carcinoma with long-term follow-up: an unusual clinical presentation
Früh M, Ruhstaller T, Neuweiler J, Cerny T. Resection of skin metastases from gastric carcinoma with long-term follow-up: an unusual clinical presentation. Onkologie 2005; 28:38-40.
Jan 1, 2005Resection of skin metastases from gastric carcinoma with long-term follow-up: an unusual clinical presentation
Jan 1, 2005Onkologie 2005; 28:38-40
Früh Martin, Ruhstaller Thomas, Neuweiler Jörg, Cerny Thomas
Hypertriglyceridemia as a possible risk factor for prostate cancer
Wuermli L, Jörger M, Henz S, Schmid H, Riesen W, Thomas G, Krek W, Cerny T, Gillessen Sommer S. Hypertriglyceridemia as a possible risk factor for prostate cancer. Prostate cancer and prostatic diseases 2005; 8:316-20.
Jan 1, 2005Hypertriglyceridemia as a possible risk factor for prostate cancer
Jan 1, 2005Prostate cancer and prostatic diseases 2005; 8:316-20
Wuermli L, Jörger Markus, Henz Samuel, Schmid H-P, Riesen W F, Thomas G, Krek W, Cerny Thomas, Gillessen Sommer Silke